Queensland University of Technology, Institute of Health and Biomedical Innovation, Australia.
Edith Cowan University, Exercise Medicine Research Institute, Australia; The University of Queensland, School of Human Movement and Nutrition Sciences, Australia.
J Sci Med Sport. 2019 Nov;22(11):1175-1199. doi: 10.1016/j.jsams.2019.05.003. Epub 2019 May 10.
Since Exercise and Sports Science Australia (ESSA) first published its position statement on exercise guidelines for people with cancer, there has been exponential growth in research evaluating the role of exercise pre-, during and post-cancer treatment.
The purpose of this report is to use the current scientific evidence, alongside clinical experience and exercise science principles to update ESSA's position statement on cancer-specific exercise prescription.
Reported in this position statement is a summary of the benefits accrued through exercise following a cancer diagnosis and the strengths and limitations of this evidence-base. An exercise prescription framework is then proposed to enable the application of cancer-specific considerations for individualisation, specificity, safety, feasibility and progression of exercise for all patients. Additional specific exercise prescription considerations are provided for the presence of haematological, musculoskeletal, systemic, cardiovascular, lymphatic, gastrointestinal, genitourinary and neurological disease- and treatment-related concerns, as well as presence of co-morbid chronic disease. Further, we also identify and discuss cancer-specific pragmatic issues and barriers requiring consideration for exercise prescription.
While for the majority, multimodal, moderate to high intensity exercise will be appropriate, there is no set prescription and total weekly dosage that would be considered evidence-based for all cancer patients. Targeted exercise prescription, which includes the provision of behaviour change advice and support, is needed to ensure greatest benefit (as defined by the patient) in the short and longer term, with low risk of harm.
自澳大利亚运动与运动科学协会(ESSA)首次发布癌症患者运动指南立场声明以来,评估癌症治疗前、治疗中和治疗后运动作用的研究呈指数级增长。
本报告旨在利用当前科学证据、临床经验和运动科学原则,更新 ESSA 关于癌症特定运动处方的立场声明。
本立场声明报告了癌症诊断后通过运动获得的益处,以及该证据基础的优势和局限性。然后提出了一个运动处方框架,以实现针对所有患者的个体化、特异性、安全性、可行性和运动进展的癌症特定考虑因素的应用。对于存在血液、肌肉骨骼、全身、心血管、淋巴、胃肠道、泌尿生殖和神经疾病以及与治疗相关的问题,以及合并慢性疾病的存在,提供了额外的特定于运动的处方考虑因素。此外,我们还确定并讨论了需要考虑的癌症特定实际问题和障碍,以进行运动处方。
虽然对于大多数人来说,多模式、中等至高强度的运动将是合适的,但没有针对所有癌症患者的基于证据的固定处方和总每周剂量。需要有针对性的运动处方,包括提供行为改变建议和支持,以确保在短期和长期内获得最大益处(由患者定义),同时风险较低。